Individual Study / HQ

Héma-Québec Seroprevalence Study

Héma-Québec Seroprevalence Study

HQ logo
Networks -
Datasets -
Variables -
Start Year
2020
Visit HQ

Members

Download
Investigators Contacts
  • Dr. Marc Germain
    Héma-Quebec
  • Dr. Marc Germain
    Héma-Quebec

Design

Study design
Cohort
Follow Up
In order to continue monitoring the evolution of COVID-19 in Quebec, the study may be repeated at regular intervals until the end of the pandemic. The first follow-up will begin in January 2021 and will continue over a 7-week period in the context of the second wave of the pandemic.

Recruitment

Recruitment Target
  • Individuals

Number of Participants

Number of Participants
7,691
Number of Participants with Biological Samples
7,691

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Timeline

HQ population

Selection Criteria
Minimum age
18
Maximum age
81
Newborns
Twins
Countries
  • Canada
Territory
Ethnic Origin
Health Status
  • Being eligible for regular blood donation (good health)
Other Criteria
Exclusion: symptoms of COVID-19 in the last 14 days prior to their donation

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Other specific population : Blood donors
Supplementary Information
The participants of this seroprevalence study were regular blood donors who completed their donation between May 25 and July 9 2020.

Number of Participants

Number of Participants
7,691
Number of Participants with Biological Samples
7,691
Data Collection Events
# Name Description Start End
0 HQ - Wave 1 Blood samples were collected for a serological test that was used to determine the presence of antibodies to SARS-CoV-2. 2020-05 2020-07
1 HQ - Nested case-control study Information was collected from participants in whom antibodies to SARS-CoV-2 had been detected. A questionnaire was completed, through a telephone interview, to collect information about the ... 2020-05 2020-07
2 HQ - Wave 2 Blood samples were collected for a serological test that was used to determine the presence of antibodies to SARS-CoV-2. 2021-01 2021-03

Classifications

Socio-demographic and economic characteristics
Lifestyle and behaviours
Birth, pregnancy and reproductive health history
Perception of health, quality of life, development and functional limitations
Diseases
Symptoms and signs
Medication and supplements
Non-pharmacological interventions
Health and community care services utilization
Death
Physical measures and assessments
Laboratory measures
Cognition, personality and psychological measures and assessments
Life events, life plans, beliefs and values
Preschool, school and work life
Social environment and relationships
Physical environment
Administrative information

Socio-demographic and economic characteristics

Age/birthdate
Sex/gender
Residence
Ethnicity, race and religion

Laboratory measures

Immunology

Administrative information

Identifiers
Date and time-related information